Aignostics

Berlin – October 16, 2026 -- Aignostics has launched HETA Clinical, a family of pan-cancer AI products aimed at the 10% to 20% of molecular tests that pathologists estimate fail because tissue contains too little tumor.

The first four products analyze whole slide H&E images across the pathology workflow, from intake and evaluation through to molecular testing. The company says the suite helps labs prioritize cases, cut turnaround time and confirm sufficient tumor content before molecular testing begins.

Four products target slide quality, tumor presence, mitoses and cellularity

HETA Quality Control measures slide quality before analysis and identifies a range of quality issues. HETA Tumor Detect annotates tumor regions and flags cases likely to contain tumor at scanning, so those cases are read first and additional stains can be ordered at intake.

Berlin – September 17, 2026 -- Aignostics has opened early access to PathoSearch, a visual search engine that retrieves diagnosed reference pathology cases from a single screenshot of an H&E slide, targeting the rare and complex cases that make up as much as 20% of a pathologist's caseload.

Database already spans 310,000 slides across 300 diagnostic entities

PathoSearch currently references more than 310,000 whole slide images drawn from over 35,000 cases, covering 300-plus diagnostic entities and 27-plus organs. The system is on track to exceed one million whole slide images by general availability. Coverage follows the WHO Classification of Tumours, focusing on malignant tumours across five organ groups -- thoracic, digestive, soft tissue and bone, female genital, and urinary and male genital -- with full coverage of all WHO-classified malignancies planned.